SCHEMBL85067

SCHEMBL85067

COC(=O)[C@H]1C[C@@H](O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 1/20 0.52
MMP2 P08253 3/20 0.46
ANPEP P15144 3/20 0.46
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 1/20 0.41
PTPN1 P18031 1/20 0.41
ATM Q13315 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 2/20 0.39
HTRA1 Q92743 1/20 0.38
P2RX3 P56373 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28027805 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL1257236 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL475537 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL1412106 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL5408514 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL84794 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL85695 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL3789795 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL611185 1.00 CYP3A4 (0.53) CYP3A4CYP1A2POLBCYP2C19ALDH1A1
SCHEMBL3188827 0.90 CYP1A2 (0.52) CYP3A4CYP1A2POLBCYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496195-A Preparation method of (R) -4, 4-difluoro pyrrolidine-2-carboxylic acid 南京优氟医药科技有限公司 2023-07-28 CN claimed
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 EP disclosed
EP-4714446-A2 PHARMACEUTICAL COMPOUNDS Nxera Pharma UK Limited (GB) 2026-03-25 EP disclosed
EP-4359402-B1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2026-03-11 EP disclosed
EP-4676929-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2026-01-14 EP disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 US disclosed
EP-4638447-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS Dark Blue Therapeutics Ltd (GB) 2025-10-29 EP disclosed
EP-4631948-A1 NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-10-15 EP disclosed
US-12384761-B2 Imidazolo indazole compounds as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-08-12 US disclosed
EP-0789707-A4 AMINO ACID NUCLEIC ACIDS ICN PHARMACEUTICALS (US) 1999-02-24 EP disclosed
US-5703243-A Intermediates for pyrrolidylthiocarbapenem derivative SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1997-12-30 US disclosed
EP-0789707-A1 AMINO ACID NUCLEIC ACIDS ICN PHARMACEUTICALS (US) 1997-08-20 EP disclosed
WO-1996014330-A1 AMINO ACID NUCLEIC ACIDS ICNPHARMACEUTICALS (US) 1996-05-17 WO disclosed
US-5385889-A Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist SCIOS NOVA INC. (US) 1995-01-31 US disclosed
EP-0618810-A4 BRADYKININ ANTAGONIST PEPTIDES. SCIOS NOVA INC (US) 1994-12-07 EP disclosed
EP-0618810-A1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 EP disclosed
US-5317016-A Pyrrolidylthiocarbapenem derivative SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1994-05-31 US disclosed
EP-0528678-A1 A pyrrolidylthiocarbapenem derivative SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1993-02-24 EP disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX CYP3A4 1904/4885CYP1A2 2158/4885POLB 1533/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 CYP3A4 4679/4885CYP1A2 4269/4885POLB 2390/4885
US-12384761-B2 Imidazolo indazole compounds as JAK inhibitors JAK1, JAK3, JAK2 CYP3A4 653/4885CYP1A2 489/4885POLB 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.